Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy

Multiple landmark trials have helped to advance the treatment of heart failure with reduced ejection fraction (HFrEF) significantly over the past decade. These trials have led to the introduction of four main drug classes into the 2021 ESC guideline, namely angiotensin-receptor neprilysin inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Malgie, Jishnu, Clephas, Pascal R. D., Brunner-La Rocca, Hans-Peter, de Boer, Rudolf A., Brugts, Jasper J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403394/
https://www.ncbi.nlm.nih.gov/pubmed/37311917
http://dx.doi.org/10.1007/s10741-023-10325-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403394/
https://www.ncbi.nlm.nih.gov/pubmed/37311917
http://dx.doi.org/10.1007/s10741-023-10325-2

Ejemplares similares